NI202000074A - Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina - Google Patents
Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolinaInfo
- Publication number
- NI202000074A NI202000074A NI202000074A NI202000074A NI202000074A NI 202000074 A NI202000074 A NI 202000074A NI 202000074 A NI202000074 A NI 202000074A NI 202000074 A NI202000074 A NI 202000074A NI 202000074 A NI202000074 A NI 202000074A
- Authority
- NI
- Nicaragua
- Prior art keywords
- modulators
- allesteric
- spiropiperidine
- nicotinic acetylcholine
- acetylcholine receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente descripción se refiere a compuestos de la fórmula I que son útiles como moduladores de alfa7 nAChR, composiciones que comprenden tales compuestos, y el uso de tales compuestos para prevenir, tratar o mejorar enfermedades, particularmente trastornos del sistema nervioso central tales como deterioros cognitivos en la enfermedad de Alzheimer, la enfermedad de Parkinson y la esquizofrenia, así como para la disquinesia inducida por L-DOPA y la inflamación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665091P | 2018-05-01 | 2018-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202000074A true NI202000074A (es) | 2021-03-05 |
Family
ID=66429709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202000074A NI202000074A (es) | 2018-05-01 | 2020-10-27 | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11332463B2 (es) |
| EP (1) | EP3788043B1 (es) |
| JP (1) | JP7073533B2 (es) |
| KR (1) | KR102587811B1 (es) |
| CN (1) | CN112119076A (es) |
| AR (1) | AR115065A1 (es) |
| AU (1) | AU2019262917B2 (es) |
| BR (1) | BR112020022088A8 (es) |
| CA (1) | CA3098583C (es) |
| CL (2) | CL2020002820A1 (es) |
| CO (1) | CO2020013462A2 (es) |
| CR (1) | CR20200509A (es) |
| EA (1) | EA202092608A1 (es) |
| EC (1) | ECSP20067907A (es) |
| GE (1) | GEP20227409B (es) |
| IL (1) | IL278154A (es) |
| JO (1) | JOP20200272A1 (es) |
| MA (1) | MA52482A (es) |
| MX (1) | MX2020011489A (es) |
| NI (1) | NI202000074A (es) |
| PE (1) | PE20210052A1 (es) |
| PH (1) | PH12020551779A1 (es) |
| SG (1) | SG11202010459XA (es) |
| TW (1) | TWI839355B (es) |
| UA (1) | UA126834C2 (es) |
| WO (1) | WO2019212927A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2020223136A1 (en) * | 2019-05-02 | 2020-11-05 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
| US20220396571A1 (en) * | 2019-11-05 | 2022-12-15 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
| JP2023510111A (ja) * | 2019-12-19 | 2023-03-13 | クリア、スペイン、エセ、ア、ウ | ウパダシチニブの調製のための方法及び中間体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR044010A1 (es) | 2003-04-11 | 2005-08-24 | Janssen Pharmaceutica Nv | Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica |
| ES2460897T3 (es) | 2007-10-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Derivados de ciclopropil aril amida y usos de los mismos |
| KR101925971B1 (ko) | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| EP2670731B1 (en) | 2011-02-02 | 2016-05-25 | Bionomics Limited | Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof. |
| US8598213B2 (en) | 2011-07-08 | 2013-12-03 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| UA111746C2 (uk) | 2011-07-08 | 2016-06-10 | Х. Луннбек А/С | Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну |
| WO2014006120A1 (en) | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| CN104884432A (zh) | 2012-08-01 | 2015-09-02 | 默沙东公司 | α7烟碱乙酰胆碱受体调节剂及其用途-I |
| CN104837820A (zh) | 2012-10-02 | 2015-08-12 | 大日本住友制药株式会社 | 咪唑衍生物 |
| EP2928860A1 (en) | 2012-12-10 | 2015-10-14 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| TW201730190A (zh) | 2015-12-24 | 2017-09-01 | Genentech Inc | Ｔｄｏ２抑制劑 |
| AR107928A1 (es) * | 2016-03-22 | 2018-06-28 | Merck Sharp & Dohme | Moduladores alostéricos de receptores de acetilcolina nicotínicos |
-
2019
- 2019-04-29 CA CA3098583A patent/CA3098583C/en active Active
- 2019-04-29 EA EA202092608A patent/EA202092608A1/ru unknown
- 2019-04-29 BR BR112020022088A patent/BR112020022088A8/pt unknown
- 2019-04-29 GE GEAP201915499A patent/GEP20227409B/en unknown
- 2019-04-29 KR KR1020207034124A patent/KR102587811B1/ko active IP Right Grant
- 2019-04-29 EP EP19722488.4A patent/EP3788043B1/en active Active
- 2019-04-29 CN CN201980029616.2A patent/CN112119076A/zh active Pending
- 2019-04-29 JP JP2020560807A patent/JP7073533B2/ja active Active
- 2019-04-29 UA UAA202007589A patent/UA126834C2/uk unknown
- 2019-04-29 JO JOP/2020/0272A patent/JOP20200272A1/ar unknown
- 2019-04-29 WO PCT/US2019/029561 patent/WO2019212927A1/en active Application Filing
- 2019-04-29 AR ARP190101126A patent/AR115065A1/es unknown
- 2019-04-29 AU AU2019262917A patent/AU2019262917B2/en active Active
- 2019-04-29 MA MA052482A patent/MA52482A/fr unknown
- 2019-04-29 MX MX2020011489A patent/MX2020011489A/es unknown
- 2019-04-29 TW TW108114867A patent/TWI839355B/zh active
- 2019-04-29 US US17/049,653 patent/US11332463B2/en active Active
- 2019-04-29 CR CR20200509A patent/CR20200509A/es unknown
- 2019-04-29 PE PE2020001722A patent/PE20210052A1/es unknown
- 2019-04-29 SG SG11202010459XA patent/SG11202010459XA/en unknown
-
2020
- 2020-10-19 IL IL278154A patent/IL278154A/en unknown
- 2020-10-26 EC ECSENADI202067907A patent/ECSP20067907A/es unknown
- 2020-10-26 CO CONC2020/0013462A patent/CO2020013462A2/es unknown
- 2020-10-27 PH PH12020551779A patent/PH12020551779A1/en unknown
- 2020-10-27 NI NI202000074A patent/NI202000074A/es unknown
- 2020-10-29 CL CL2020002820A patent/CL2020002820A1/es unknown
-
2021
- 2021-07-06 CL CL2021001795A patent/CL2021001795A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| NI202000074A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
| CL2009000975A1 (es) | Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer. | |
| DOP2014000230A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| ECSP15004780A (es) | Antagonistas del receptor de 5ht3 | |
| UY35628A (es) | ?compuestos heteroaromáticos y su uso como ligandos d1 de dopamina?. | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| BR112016022575A2 (pt) | Composições e métodos para o tratamento de doenças neurodegenerativas | |
| UY34281A (es) | "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
| CL2009000149A1 (es) | Compuestos heterociclos que incluyen un grupo ciclobutoxi sustituido ligandos del receptor h3 composicion farmaceutica que los comprende utiles para tratar enfermedades del sistema nervioso central, tales como deterioro cognitivo leve, alzheimer, trastornos de la memoria, enfermedad de parkinson, esquizofrenia y demencia. | |
| CL2012000539A1 (es) | Compuestos derivados de acido 3-(morfolin-4-il)-propionico, moduladores de s1p; composicion farmaceutica; utiles en el tratamiento, alivio o prvencion de enfermedades del sistema nervioso central, tales como trastornos neurodegenerativas, enfermedades de alzheimer, depresion mayor, autismo, entre otras. |